10x Genomics, a global leader in single cell and spatial biology, announced the launch of Xenium Protein, the newest addition to its Xenium Spatial platform. The breakthrough technology enables researchers to simultaneously detect RNA and protein in the same cell, on the same tissue section, and within a single automated run-marking the first fully integrated spatial multiomic workflow on the Xenium platform. This advancement allows scientists to uncover deeper biological insights with higher confidence, without relying on multiple, fragmented technologies.
“Scientists can now analyze RNA and protein together, streamlining workflows, removing the need for complex data integration and unlocking more precise insights,” said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. “Integrated multiomic analysis is essential to advancing our understanding of complex diseases and accelerating therapeutic discovery.”
Xenium Protein introduces ready-to-use protein subpanels designed to work seamlessly with RNA panels on the same slide. These panels include dozens of well-characterized proteins linked to cell growth, signaling, and immune response-making them especially powerful for advancing research in oncology, immunology, and other complex disease areas.
Also Read: Ryght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors
By combining RNA and protein detection into a single workflow, Xenium Protein eliminates the need for separate sample sections or disparate technologies. The result is a simplified experimental design, reduced time to insight, and faster progress from discovery through translational research.
Early access users are already applying Xenium Protein across diverse areas of study, including large-scale atlasing efforts and therapeutic research.
“Integrating RNA and protein analysis within the same Xenium workflow enables a comprehensive view of tissue architecture and cell-cell interactions in a single experiment,” said Dr. Julien Tessier, Principal Scientist, Sanofi. “This integrated multiomics approach removes the reliance on data co-registration – which is often complex and can introduce uncertainty – while delivering critical insights into target and biomarker expression that RNA alone often fails to capture.”